Solventum Corporation (SOLV)

Solventum's stock experienced several notable events in the past six months. The stock began trading on April 1, 2024, after its spin-off from 3M. Solventum reported its Q1 2025 earnings on May 8, 2025. On August 7, 2025, Solventum reported Q2 results that surpassed expectations, leading to a 2% jump in its shares. On September 2, 2025, Solventum completed the sale of its Purification & Filtration business to Thermo Fisher Scientific Inc. Solventum announced the pricing of a secondary offering of 8,800,000 shares of its common stock. Solventum commenced offers to purchase its outstanding notes for up to $1.75 billion, later upsized to $2.0 billion. On October 21, 2025, Solventum appointed Heather Knight as Chief Commercial Officer. While the S&P 500 was up 24.4% since April 2025, Solventum lagged with an 8.1% return, though it outperformed the Health Care Select Sector SPDR Fund's 6.3% increase over the same period. As of October 23, 2025, the share price was $72.28, representing a decline of 1.26% from October 24, 2024.

Information directly addressing the demand seasonality for Solventum's specific products and services is not explicitly detailed. Demand for many of its products might be relatively stable due to ongoing healthcare needs. Certain medical supplies might see increased demand during flu seasons or other public health events. The company's focus on "critical customer and patient needs" suggests a consistent demand base.

Solventum Corporation is an American healthcare company spun off from 3M on April 1, 2024, headquartered in Maplewood, Minnesota. It operates as a global innovator in healthcare solutions, using material science, data science, and digital capabilities. Solventum's core businesses are MedSurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The MedSurg segment provides solutions for wound care, skin care, sterilization, temperature management, and surgical supplies. The Dental Solutions segment offers dental and orthodontic products. The Health Information Systems segment provides software solutions and services for healthcare systems. The Purification and Filtration segment delivers purification and filtration technologies; however, this segment was sold to Thermo Fisher Scientific Inc. on September 2, 2025.

Solventum Corporation has a significant international presence, operating in 28 countries with over 20,000 employees and more than 300 offices/facilities worldwide. The company serves hospitals, clinics, dental practices, and other healthcare providers globally.

Solventum carries a legacy of over 70 years of healthcare innovation from its predecessor, 3M. The company's mission is to enable better, smarter, safer healthcare to improve lives. In the past year, Solventum was placed on the Fortune 500 and named a best company to work for by U.S. News & World Report, indicating a positive brand reputation.

Approximately 66.21% of Solventum's stock is held by institutional shareholders, 14.90% by Solventum insiders, and 18.89% by retail investors. Major institutional owners include Vanguard Group Inc., Independent Franchise Partners LLP, and BlackRock, Inc. The largest individual Solventum shareholder is "Co 3m," owning 25.57 million shares, representing 14.78% of the company. 3M Company also owns the most shares of Solventum.